Phaseline

Companies › Tioga Pharmaceuticals

Tioga Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Asimadoline (TP0052)
Kappa opioid receptor agonist
OPRK1Phase 2Vasomotor SymptomsOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07042516Asimadoline (TP0052)Phase 2Vasomotor SymptomsGenitourinaryOct 2027

Targets

OPRK1 (1)

Companies with the same targets

Trevi Therapeutics Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Boulder Care Adneuris Therapeutics Johnson & Johnson (Janssen) Alkermes Vifor Fresenius Medical Care Renal Pharma

Companies built like this

Vifor Fresenius Medical Care Renal Pharma Azure Biotech Gesynta Pharma Suzhou Sanegene Bio R1 Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.